- Home
- ICON vs ALZN Comparison
ICON vs ALZN Comparison
Compare ICON & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICON | ALZN |
|---|---|---|
| Founded | 2023 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ICON | ALZN |
|---|---|---|
| Price | $1.41 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 111.5K | 41.2K |
| Earning Date | 02-24-2026 | 03-11-2026 |
| Dividend Yield | ★ 4754.20% | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.33 | N/A |
| Revenue Next Year | $23.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.84 |
| 52 Week High | $4.23 | $8.22 |
Technical Indicators
Market Signals| Indicator | ICON | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 66.32 | 44.19 |
| Support Level | $0.72 | $1.03 |
| Resistance Level | $1.76 | $1.21 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 84.91 | 43.75 |
Price Performance
Historical ComparisonAbout ICON Icon Energy Corp.
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.